JP7252963B2 - ダントロレンの生産物およびそれらの使用方法 - Google Patents

ダントロレンの生産物およびそれらの使用方法 Download PDF

Info

Publication number
JP7252963B2
JP7252963B2 JP2020542711A JP2020542711A JP7252963B2 JP 7252963 B2 JP7252963 B2 JP 7252963B2 JP 2020542711 A JP2020542711 A JP 2020542711A JP 2020542711 A JP2020542711 A JP 2020542711A JP 7252963 B2 JP7252963 B2 JP 7252963B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
aspects
dantrolene
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500405A5 (https=
JP2021500405A (ja
Inventor
ウェスコット、チャールズ
ヘプナー、エイドリアン
ラーソン、アリッサ
Original Assignee
イーグル リサーチ ラブズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーグル リサーチ ラブズ リミテッド filed Critical イーグル リサーチ ラブズ リミテッド
Publication of JP2021500405A publication Critical patent/JP2021500405A/ja
Publication of JP2021500405A5 publication Critical patent/JP2021500405A5/ja
Priority to JP2023007969A priority Critical patent/JP2023061949A/ja
Application granted granted Critical
Publication of JP7252963B2 publication Critical patent/JP7252963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
JP2020542711A 2017-10-20 2018-10-19 ダントロレンの生産物およびそれらの使用方法 Active JP7252963B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023007969A JP2023061949A (ja) 2017-10-20 2023-01-23 ダントロレンの生産物およびそれらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762575124P 2017-10-20 2017-10-20
US62/575,124 2017-10-20
US201862674422P 2018-05-21 2018-05-21
US62/674,422 2018-05-21
PCT/US2018/056713 WO2019079721A1 (en) 2017-10-20 2018-10-19 DANTROLENE PRODRUGS AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023007969A Division JP2023061949A (ja) 2017-10-20 2023-01-23 ダントロレンの生産物およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2021500405A JP2021500405A (ja) 2021-01-07
JP2021500405A5 JP2021500405A5 (https=) 2021-09-09
JP7252963B2 true JP7252963B2 (ja) 2023-04-05

Family

ID=64277793

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542711A Active JP7252963B2 (ja) 2017-10-20 2018-10-19 ダントロレンの生産物およびそれらの使用方法
JP2023007969A Pending JP2023061949A (ja) 2017-10-20 2023-01-23 ダントロレンの生産物およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023007969A Pending JP2023061949A (ja) 2017-10-20 2023-01-23 ダントロレンの生産物およびそれらの使用方法

Country Status (19)

Country Link
US (3) US11352347B2 (https=)
EP (2) EP4574832A3 (https=)
JP (2) JP7252963B2 (https=)
KR (1) KR102652642B1 (https=)
CN (1) CN111344286A (https=)
AU (2) AU2018351494C1 (https=)
BR (1) BR112020007858A2 (https=)
CA (1) CA3079558A1 (https=)
CO (1) CO2020006193A2 (https=)
ES (1) ES3016835T3 (https=)
IL (1) IL274045B2 (https=)
MA (1) MA50403A (https=)
MX (2) MX2020003400A (https=)
MY (1) MY201417A (https=)
NZ (1) NZ763377A (https=)
SG (1) SG11202003452XA (https=)
UA (1) UA127738C2 (https=)
WO (1) WO2019079721A1 (https=)
ZA (1) ZA202002779B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020007858A2 (pt) * 2017-10-20 2020-10-27 Eagle Research Labs Limited composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto
SG11202104833YA (en) * 2018-11-27 2021-06-29 Eagle Res Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods
IL296517A (en) * 2020-04-10 2022-11-01 Eagle Pharmaceuticals Inc Methods of treating sars-cov-2 infections
US20230149364A1 (en) * 2020-04-10 2023-05-18 Eagle Pharmaceuticals, Inc. Methods of treating viral infections
WO2021207445A1 (en) 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating coronavirus infections
WO2021207444A1 (en) 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating severe acute respiratory syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500570A (ja) 2007-10-09 2011-01-06 ユーエス ワールドメッズ リミテッド ライアビリティ カンパニー ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) * 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4137402A (en) 1978-03-30 1979-01-30 Morton-Norwich Products, Inc. Quaternary ammonium salts of dantrolene and clodanolene
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20080206332A1 (en) 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2009067175A2 (en) 2007-11-16 2009-05-28 Nektar Therapeutics Al, Corporation Oligomer-dantrolene conjugates and related compounds
US20090306163A1 (en) 2008-06-10 2009-12-10 Pamela Renee Lipkin Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling
FR2944525B1 (fr) 2009-04-17 2011-06-24 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
EP2765860B1 (en) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
CN105209030B (zh) 2013-03-15 2018-06-12 罗莎琳德富兰克林医科大学 用于稳定兰尼碱受体使其免于异常水平的钙释放的化合物
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
CA2946253C (en) 2013-05-06 2022-08-09 University Health Network Methods of administering dantrolene for the acute treatment of cardiac arrhythmias
EP2994132A4 (en) 2013-05-08 2016-11-16 Univ Howard COMPOSITIONS AND METHOD FOR TREATING NEURONAL ISCHEMIC REPERFUSION DAMAGE
HUP1300720A2 (hu) 2013-12-12 2015-06-29 Univ Szegedi Gyógyászati készítmények sebgyógyulás elõsegítésére
JPWO2015182625A1 (ja) 2014-05-26 2017-06-08 国立大学法人京都大学 Ｒａｓ活性阻害薬及びその用途
WO2016077706A1 (en) 2014-11-13 2016-05-19 Washington University Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
CN108366963A (zh) 2015-10-20 2018-08-03 B.布劳恩梅尔松根股份公司 包含丹曲林的水性组合物
BR112020007858A2 (pt) * 2017-10-20 2020-10-27 Eagle Research Labs Limited composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto
SE542780C2 (en) 2018-09-15 2020-07-07 Coloreel Group AB A system and method for in-line treatment of thread

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500570A (ja) 2007-10-09 2011-01-06 ユーエス ワールドメッズ リミテッド ライアビリティ カンパニー ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bundgaard, Hans; Johansen, Marianne，Pro-drugs as drug delivery systems. VIII. Bioreversible derivatization of hydantoins by N-hydroxymethylation，International Journal of Pharmaceutics ，1980年，5(1)，67-77

Also Published As

Publication number Publication date
AU2023278113B2 (en) 2025-09-04
SG11202003452XA (en) 2020-05-28
EP3697779B1 (en) 2025-03-05
US20250145593A1 (en) 2025-05-08
MA50403A (fr) 2021-04-28
JP2021500405A (ja) 2021-01-07
UA127738C2 (uk) 2023-12-20
US20200239455A1 (en) 2020-07-30
AU2018351494B2 (en) 2023-09-14
ZA202002779B (en) 2023-10-25
US12269815B2 (en) 2025-04-08
KR20200072514A (ko) 2020-06-22
EP4574832A2 (en) 2025-06-25
MX2023010501A (es) 2023-09-20
RU2020116367A3 (https=) 2021-11-26
CO2020006193A2 (es) 2020-08-21
US20220324850A1 (en) 2022-10-13
AU2018351494A1 (en) 2020-04-30
WO2019079721A1 (en) 2019-04-25
BR112020007858A2 (pt) 2020-10-27
AU2023278113A1 (en) 2024-01-04
CN111344286A (zh) 2020-06-26
ES3016835T3 (en) 2025-05-09
EP3697779A1 (en) 2020-08-26
IL274045A (en) 2020-06-30
MX2020003400A (es) 2020-09-18
AU2018351494C1 (en) 2025-10-23
IL274045B1 (en) 2023-05-01
JP2023061949A (ja) 2023-05-02
US11352347B2 (en) 2022-06-07
CA3079558A1 (en) 2019-04-25
RU2020116367A (ru) 2021-11-22
EP4574832A3 (en) 2025-09-17
NZ763377A (en) 2026-03-27
MY201417A (en) 2024-02-21
IL274045B2 (en) 2023-09-01
KR102652642B1 (ko) 2024-04-01

Similar Documents

Publication Publication Date Title
JP7252963B2 (ja) ダントロレンの生産物およびそれらの使用方法
TWI499412B (zh) 苯基硫乙酸酯組合物及其使用方法
JP2025010154A (ja) 線維症及び炎症の処置のための組成物
TWI633887B (zh) 用於預防及／或治療多囊性腎臟病之藥物
US10668036B2 (en) Deuterated analogs of D-serine and uses thereof
US12102616B2 (en) Psilocin mucate
KR20210032403A (ko) 7-아미노-5-티오-티아졸로[4,5-d]피리미딘의 포스페이트 및 포스포네이트 유도체, 및 CX3CR1 및/또는 CX3CL1의 상승된 수준과 관련된 병태를 치료하는 데 있어서의 이들의 용도
US11384084B2 (en) First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents
RU2815017C2 (ru) Пролекарства дантролена и способы их применения
CN104321323B (zh) 碳环核苷及其医药用途和组合物
HK40036032B (en) Dantrolene prodrugs and methods of their use
HK40036032A (en) Dantrolene prodrugs and methods of their use
KR20100031590A (ko) 광학 활성 Ｎ-(α-머캅토프로피오닐)글라이신
US20260008750A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220923

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230123

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230130

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230324

R150 Certificate of patent or registration of utility model

Ref document number: 7252963

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250